bioRxiv Science⌕ Search

Biology subjects

Bosso, M.

Publications and source records attributed to Bosso, M..

2 recordsLinked to original sources

A novel in vitro 3D cancer model based on modular tissue engineering approach

An emerging tool to better recapitulate the complexity of tumor biology in vitro is 3D culture models. Here, we describe a free-floating collagen-based hydrogel system with embedded cancer cells, called microtissues. The microtissues are based on the well-established modular tissue engineering method. They mimic the natural development of the tumor microenvironment, with features such as hypoxia and treatment resistance. To demonstrate the utility of microtissues as a 3D tumor model system, triple negative breast cancer cells were cultured using this method and were shown to maintain cell viability and proliferation with minimal cell death, along with mimicking natural emergence of tumor properties such as, a hypoxic core. Furthermore, by screening the model with commonly used anti-breast cancer chemotherapeutics, we observed drug resistance to concentrations which are largely in accordance with the used doses in the clinics. Therefore, our model offers the opportunity to naturally reproduce fundamental features of a tumor in vitro, leading to emergence of a similar cell reprogramming which is responsible for clinical drug resistance.

cancer biology↗

Deep generative models predict SARS-CoV-2 Spike infectivity and foreshadow neutralizing antibody escape

Recurrent waves of SARS-CoV-2 infection, driven by the periodic emergence of new viral variants, highlight the need for vaccines and therapeutics that remain effective against future strains. Yet, our ability to proactively evaluate such therapeutics is limited to assessing their effectiveness against previous or circulating variants, which may differ significantly in their antibody escape from future viral evolution. To address this challenge, we develop a deep learning method to predict the effect of mutations on fitness and escape from neutralizing antibodies. We use this model to engineer 83 unique SARS-CoV-2 Spike proteins incorporating novel combinations of up to 46 amino acid changes relative to the ancestral B.1 variant. The designed constructs were infectious and evaded neutralization by nine well-characterized panels of human polyclonal anti-SARS-CoV-2 immune sera (from vaccinated, boosted, bivalent boosted, and breakthrough infection individuals). Designed constructs on contemporary SARS-CoV-2 strains displayed similar levels of antibody neutralization escape and similar antigenic profiles as variants seen subsequently (up to 12 months later) during the COVID-19 pandemic despite differences in exact mutations. Our approach provides targeted datasets of antigenically diverse escape variants for an early evaluation of the protective ability of vaccines and therapeutics to inhibit not only currently circulating but also future variants. This approach is generalizable to other viral pathogens.

immunology↗